Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-510- Thrombospondin-1 Mimetic · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| ABT-510 - Thrombospondin-1 mimetic | DRUG | - |
Inclusion Criteria A subject will be eligible for study participation if all of the following criteria are met: * The subject is at least 18 years of age. * The subject has histologically confirmed high grade locally advanced or metastatic soft tissue sarcoma (excluding Ewings sarcoma and chondros...
ABT-510 is a small molecule being studied for the treatment of cancer, specifically soft tissue sarcoma and non-Hodgkin lymphoma. It is an investigational drug developed by Abbott Laboratories and is not yet approved for any use.
ABT-510 is a thrombospondin-1 mimetic, meaning it mimics the activity of the naturally occurring protein thrombospondin-1. This protein is known to inhibit angiogenesis, the process by which new blood vessels form, which is important in tumor growth and metastasis.
ABT-510 is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. The drug is currently in clinical development for oncology indications.
ABT-510 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in soft tissue sarcoma and one in lymphoma. The drug remains investigational and has not received FDA approval.
ABT-510 has completed two Phase 2 trials. NCT00061659 evaluated the drug in 88 patients with locally advanced or metastatic soft tissue sarcoma. NCT00061672 evaluated the drug in 67 patients with refractory lymphoma, including non-Hodgkin and Hodgkin's lymphoma. Both trials were conducted in the United States.
ABT-510 is not the same as thrombospondin-1; it is a mimetic, meaning it is designed to mimic the effects of thrombospondin-1. The drug is a synthetic small molecule that aims to replicate the anti-angiogenic properties of the natural protein.